



ENLIGHT Newsletter

We are excited that EDAP continues to make substantial progress with our U.S. clinical ENLIGHT trial. In the attached newsletter, please find a message from Cary Robertson, MD, the trial's Primary Investigator and John Rewcastle, PhD, EDAP's Medical Director, outlining the success of our patient awareness program, which has been instrumental in driving our accrual efforts at participating sites.

During the last two months, additional clinical centers have received IRB approval, including the world renowned Memorial Sloan Kettering and M.D. Anderson Cancer Centers. These leading prostate cancer treatment sites enhance the credibility of our overall Ablatherm-HIFU technology and raise EDAP's profile among the urological community.

We look forward to providing further clinical updates as we progress in the coming months.

Yours sincerely,

Marc Oczachowski
Chief Executive Officer
EDAP-TMS